13.86USD-3.55%Mkt Cap: 518.18M USDP/E: —Last update: 2026-05-22
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap518.18M USD
Enterprise Value297.87M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.98M USD
Revenue/Share—
Last Price13.86 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees51
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.92
PEG—
EV/EBITDA-4.48
EV/Revenue—
P/S—
P/B2.15
EPS (TTM)-1.94
EPS (Forward)-1.81
52W Range
3.35081% of range16.33
52W High16.33 USD
52W Low3.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.98%
ROA-21.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-55.31M USD
CapEx (TTM)231.00K USD
FCF Margin—
FCF Yield-7.53%
Net Debt-239.37M USD
Net Debt/EBITDA3.60
Balance Sheet
Debt/Equity0.03
Current Ratio38.00
Quick Ratio37.00
Book Value/Sh6.688 USD
Cash/Share6.589 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)22.33 USD
Target Range16.00 USD – 28.00 USD
# Analysts6
Ownership
Shares Out.32.72M
Float27.59M
Insiders0.98%
Institutions93.93%
Short Interest
Short Ratio6.4d
Short % Float4.93%
Short % Out.4.29%
Shares Short1.61M
Short (prev mo.)2.78M
Technical
SMA 5013.23 (+4.8%)
SMA 20012.13 (+14.3%)
Beta0.89
S&P 52W Chg28.31%
Avg Vol (30d)243.27K
Avg Vol (10d)141.50K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—